FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 126 filers reported holding FATE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $2,536,000 | +41.8% | 144,340 | +3.5% | 0.00% | 0.0% |
| Q4 2018 | $1,788,000 | -40.6% | 139,394 | -24.5% | 0.00% | +50.0% |
| Q3 2018 | $3,010,000 | +191.4% | 184,722 | +102.8% | 0.00% | +100.0% |
| Q2 2018 | $1,033,000 | +24.2% | 91,078 | +6.9% | 0.00% | 0.0% |
| Q1 2018 | $832,000 | +91.7% | 85,232 | +20.1% | 0.00% | 0.0% |
| Q4 2017 | $434,000 | +54.4% | 70,992 | 0.0% | 0.00% | – |
| Q3 2017 | $281,000 | +20.6% | 70,992 | -1.4% | 0.00% | – |
| Q2 2017 | $233,000 | – | 71,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |